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Abstract 
 
 The immature phenotype of human pluripotent stem cell derived cardiomyocytes 
(hPSC-CM) is currently the main drawback limiting the potential of these cells for 
applications in cell therapy and pre-clinical research. Herein, it was assessed whether 
alteration of hPSC-CM culture medium composition to mimic in vivo substrate availability 
during cardiac development would induce hPSC-CM maturation in vitro.  
 Initial qualitative proteomic characterization of both stem cell and differentiated 
cultures revealed that although hPSC-CMs remain highly glycolytic, like their pluripotent 
counterparts, there is an evident development in oxidative metabolic machinery, together with 
enrichment in cardiac markers, during differentiation to a cardiac lineage. Parallel labeling 
experiments and 13C-MFA were used for the estimation of intracellular flux distributions, 
which coupled with structural analysis allowed to elucidate the impact of distinct carbon 
sources in the metabolic profile and maturation status of hiPSC-CMs. Culture of hiPSC-CMs 
in media with distinct carbon sources (glucose, lactate, fatty acids and galactose) proved that 
hiPSC-CMs exhibit remarkable metabolic plasticity, being able to shift to an oxidative 
metabolism, in the absence of glucose. From the assorted selection of media tested, cell 
culture in fatty acid medium supplemented with galactose was the most efficient in improving 
hiPSC-CMs maturation, as cells display an oxidative metabolism and show an elongated 
morphology with highly organized sarcomeric structures. Furthermore, galactose improved 
fatty acid oxidation by increasing oxidative capacity thus preventing lipotoxic effects of fatty 
acid accumulation. In standard glucose rich medium, hiPSC-CMs maintain a fetal-like 
metabolic profile and display features that resemble pathogenic hypertrophy. 
 This thesis reports for the first time not only a metabolic network model of hiPSC-
CMs cultured in distinct media, but also important insights on how substrate change 
modulates metabolic and structural maturation of hiPSC-CMs. As such, this work represents a 
relevant step forward in time efficient maturation of hiPSC-CMs, facilitating the use of this 
promising cell type in clinical and pre-clinical applications.  
 
 
Keywords: Human pluripotent stem cells derived cardiomyocytes (hPSC-CMs); 
Cardiomyocyte maturation; Fatty Acids; Galactose; Metabolic Flux Analysis 
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Resumo 
 
 Atualmente, e apesar dos grandes avanços na medicina, as doenças cardiovasculares 
continuam a ser a principal causa de morte a nível mundial. Muitas destas doenças, como por 
exemplo o enfarte do miocárdio, estão associadas a uma grande perda permanente de 
cardiomiócitos, uma população celular não proliferativa e terminalmente diferenciada. Assim, 
dos tratamentos existentes apenas o transplante cardíaco permite compensar tanto a perda 
celular como restaurar de forma eficiente a função cardíaca. No entanto, a implementação 
desta intervenção cirúrgica como tratamento convencional é restringida pelo número limitado 
de órgãos compatíveis doados.  
 A capacidade de proliferação ilimitada das células estaminais pluripotentes humanas 
(hPSC do acrónimo inglês human pluripotent stem cell), em conjunto com protocolos de 
diferenciação direcionada eficientes, permitem a produção de vários tipos específicos de 
células humanas, incluindo cardiomiócitos. Estas células podem ser usadas numa vasta 
panóplia de aplicações tal como, medicina regenerativa, rastreio de novos medicamentos ou 
como modelo celular para avaliar o desenvolvimento e progressão de várias doenças. Apesar 
do progresso alcançado ao longo dos anos no aumento da eficiência dos protocolos de 
diferenciação, a população final de cardiomiócitos derivados de hPSC (hPSC-CMs) obtida 
apresenta um fenótipo imaturo quer em termos de estrutura, expressão génica, metabolismo 
ou electrofisiologia. Por isto, o estado imaturo dos hPSC-CMs é atualmente o principal fator a 
limitar o potencial destas células em terapia celular e investigação pré-clinica. 
 Portanto, o objetivo deste estudo centra-se na avaliação do impacto da alteração da 
composição do meio de cultura dos hPSC-CMs, por forma a mimetizar os substratos 
disponíveis durante o desenvolvimento in vivo do coração humano, na maturação de hPSC-
CMs in vitro. 
 Duas linhas de células estaminais, uma de células estaminais embrionárias humanas 
(hESC) e outra de hPSC induzidas (hiPSC), foram diferenciadas usando um protocolo 
recentemente implementado para a diferenciação direcionada de cardiomiócitos em mono-
camadas bidimensionais. Análise por citometria de fluxo permitiu garantir a eficiência da 
metodologia aplicada assim como determinar a pureza da população de cardiomiócitos obtida. 
Adicionalmente, análise qualitativa do proteoma total de ambas as linhas de células 
estaminais, antes e após diferenciação, revelou um enriquecimento significativo, em funções 
biológicas relacionadas com a função cardíaca, após 15 dias de diferenciação. Por outro lado, 
a análise das principais vias metabólicas mostrou um enriquecimento acentuado em vias como 
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fosforilação oxidativa, ciclo do TCA, glicólise e β-oxidação de ácidos gordos, após 15 dias de 
diferenciação. A análise destes resultados revela que durante a diferenciação de células 
estaminais para uma linhagem cardíaca existe um desenvolvimento em termos de maquinaria 
metabólica oxidativa, apesar de tanto as hPSC como os hPSC-CMs se manterem 
principalmente glicolíticos. Deste modo procedeu-se com um estudo metabólico detalhado 
para avaliar a possível existência de uma relação entre a fonte de carbono disponível no meio 
de cultura e o perfil metabólico das células.  
 Após 15 dias de diferenciação, hiPSC-CMs foram mantidos durante mais 20 dias em 
meio de cultura sem glucose mas suplementado quer com: i) ácidos gordos (FAM), ii) 
galactose e ácidos gordos (GFAM), iii) lactato durante os primeiros 10 dias seguido de uma 
troca para galactose e ácidos gordos durante o restante tempo em cultura (LACM&GFAM), 
além da condição controlo em meio rico em glucose (GLCM). Várias técnicas de 
metabolómica como HPLC e GC-MS, assim como análise estrutural recorrendo a microscopia 
de imunofluorescência, foram usadas ao longo da cultura, para avaliar o impacto do uso de 
fontes de carbono distintas no perfil metabólico e estrutural de hiPSC-CMs. 
 Uma primeira análise dos dados metabólicos confirmou que hiPSC-CMs em GLCM, 
mantêm um perfil metabólico dependente de glicólise anaeróbica sem qualquer melhoria na 
capacidade oxidativa ao longo do tempo em cultura. Este resultado foi comprovado pela taxa 
de produção de lactato elevada, do qual cerca de 90% advém da metabolização de glucose, e 
pela fração inalterada de incorporação em intermediários do ciclo do TCA. No entanto, na 
ausência de glucose, hiPSC-CMs demonstraram uma plasticidade metabólica notável ao 
consumirem as fontes de carbono distintas suplementadas no meio. Por outro lado, nestes 
meios sem glucose não se verifica a dependência de glicólise anaeróbica, visto que em 
nenhuma destas condições houve produção de lactato. Estes resultados sugerem que quando o 
principal substrato disponível no meio de cultura é glucose, o consumo preferencial deste 
substrato restringe os hiPSC-CMs a um metabolismo glicolítico. Portanto, o desenvolvimento 
em termos de maquinaria metabólica durante a diferenciação de hiPSC-CMs, verificado 
através da análise do proteoma total, poderá refletir uma adaptação inerente dos hiPSC-CMs 
para o consumo de diversas fontes de carbono e transição para um metabolismo oxidativo.  
 Para uma caracterização mais detalhada das alterações metabólicas em hiPSC-CMs, as 
taxas de consumo e produção de metabolitos assim como os dados de incorporação de 
isótopos 13C foram integrados num modelo da rede metabólica celular, através de 13C-MFA 
não estacionário. Esta técnica baseia-se no recurso a simulação computacional para estimar 
um conjunto de fluxos metabólicos intracelulares que minimizem a variância da soma dos 
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quadrados dos resíduos entre os valores previstos pelo modelo e os medidos 
experimentalmente. Os modelos metabólicos obtidos ao final do tempo de cultura confirmam 
os resultados preliminares, de que: i) em GLCM, os hiPSC-CMs permanecem principalmente 
glicolíticos, no qual a maior parte do piruvato citosólico é desviado para a produção de 
lactato; ii) nas restantes condições se verifica a transição para um metabolismo oxidativo, com 
um aumento significativo na contribuição do ciclo de TCA e da β-oxidação de ácidos gordos. 
Todavia, em FAM, a maior parte dos ácidos gordos que entram na célula são desviados para 
acumulação nas reservas internas (gotículas lipídicas). Um resultado confirmado com recurso 
a um kit comercial para a quantificação destas reservas, o que justifica a baixa viabilidade 
observada nas células cultivadas neste meio dado o efeito tóxico da acumulação excessiva de 
lípidos. 
 Da seleção de diferentes meios testados, a cultura em meio suplementado com 
galactose e ácidos gordos (GFAM) provou ser a mais eficiente a promover a maturação de 
hiPSC-CMs in vitro. Aqui, os hiPSC-CMs além de serem caracterizados por um perfil 
metabólico principalmente oxidativo apresentam também uma morfologia alongada e 
estruturas sarcoméricas com um elevado nível de organização. Todos estes fatores referidos 
são característicos de cardiomiócitos humanos adultos. Adicionalmente, a presença de 
galactose melhorou a oxidação de ácidos gordos ao aumentar a capacidade oxidativa total, 
prevenindo desta forma os efeitos tóxicos da acumulação de lípidos. Pelo contrário, os hiPSC-
CMs mantidos na condição controlo, ou seja em meio rico em glucose (GLCM), apresentam 
um metabolismo glicolítico, tal como cardiomiócitos fetais, além de que possuem uma 
morfologia arredondada, área celular maior e sarcómeros desorganizados, estando todas estas 
características associadas a hipertrofia patológica. Estes resultados evidenciam a importância 
do papel regulatório do metabolismo numa variedade ampla de funções celulares.  
 Neste estudo é reportado pela primeira vez um modelo da rede metabólica de hiPSC-
CMs cultivados com distintas fontes de carbono, obtido através de 13C-MFA não estacionário, 
assim como, é explorado o nível ao qual esta mudança na disponibilidade de substratos regula 
a maturação metabólica e estrutural dos hiPSC-CMs. O protocolo de maturação estabelecido 
neste estudo apresenta vantagens técnicas e económicas em relação às abordagens existentes, 
dada a sua simplicidade (uma simples mudança de meio de cultura) e facilidade de aplicação 
(não requer equipamento específico ou adição de fatores/químicos caros). De notar que, 10 
dias de cultura em GFAM foi suficiente para promover um nível de maturação metabólica e 
estrutural dos hiPSC-CMs comparável ao que tem sido reportado na literatura em culturas de 
longo prazo.  
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 No cômputo geral, a metodologia aqui desenvolvida constitui um avanço relevante no 
desenvolvimento de estratégias eficientes de maturação de hiPSC-CMs, facilitando a 
transferência de hiPSC-CMs para aplicações em terapia celular, testes de toxicidade, 
descoberta de novos medicamentos e modelos celulares de doenças cardíacas.   
 
 
Palavras-chave: cardiomiócitos derivados de células estaminais pluripotentes humanas 
(hPSC-CMs); maturação de cardiomiócitos; ácidos gordos; galactose; análise de fluxo 
metabólico.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
viii 
 
Index 
 
Acknowledgments ....................................................................................................................... i 
Preface ........................................................................................................................................ ii 
Abstract ..................................................................................................................................... iii 
Resumo ...................................................................................................................................... iv 
List of Figures ............................................................................................................................ x 
List of Tables .............................................................................................................................. x 
Abbreviation list ........................................................................................................................ xi 
1. Introduction ......................................................................................................................... 1 
1.1. Stem cell-based therapies for cardiac repair .................................................................... 1 
1.2. Human pluripotent stem cells .......................................................................................... 2 
1.3. Cardiomyocyte differentiation and enrichment ............................................................... 3 
1.4. Maturation of hPSC-CMs ................................................................................................ 4 
1.5. Cardiomyocyte structure and contraction ........................................................................ 5 
1.6. Metabolic dynamics during heart development............................................................... 7 
1.7. Metabolic Flux Analysis .................................................................................................. 8 
2. Aim of the thesis ................................................................................................................. 9 
3. Materials and Methods ...................................................................................................... 10 
3.1. Cell Culture.................................................................................................................... 10 
3.1.1. hPSC maintenance and differentiation to cardiomyocytes ..................................... 10 
3.1.2. hiPSC-CM maturation ............................................................................................ 10 
3.1.3. Cell concentration and viability .............................................................................. 10 
3.2. Characterization of hPSC-CMs ..................................................................................... 11 
3.2.1. Flow cytometry analysis ......................................................................................... 11 
3.2.2. Qualitative total proteome analysis ......................................................................... 11 
3.3. Nonstationary 13C-Metabolic Flux Analysis ................................................................. 12 
3.3.1. Metabolite analysis ................................................................................................. 12 
ix 
 
3.3.2. Isotopic tracer experiments and GC-MS analysis ................................................... 12 
3.3.3. Metabolic network and nonstationary 13C-MFA .................................................... 13 
3.3.4. ATP production ....................................................................................................... 13 
3.4. Assessment of hiPSC-CM structure .............................................................................. 13 
3.4.1. Immunofluorescence microscopy ........................................................................... 13 
3.4.2. Cell morphology ..................................................................................................... 13 
3.4.3. Measurement of mitochondrial membrane potential .............................................. 13 
3.4.4. Lipid droplets content ............................................................................................. 14 
3.5. Statistical analysis.......................................................................................................... 14 
4. Results and Discussion ..................................................................................................... 15 
4.1. hPSC-CMs remain highly glycolytic regardless of metabolic development during 
differentiation ....................................................................................................................... 15 
4.2. hiPSC-CMs shift to an oxidative metabolism in the absence of glucose ...................... 19 
4.3. Supplementation of fatty acid medium with galactose prevents lipotoxicity ................ 23 
4.4. GFAM improves morphology and structure of hiPSC-CMs ......................................... 25 
5. Conclusion ........................................................................................................................ 29 
6. References ......................................................................................................................... 30 
7. Annexes ............................................................................................................................. 34 
 
 
 
 
 
 
 
 
 
 
 
 
x 
 
List of Figures 
 
Figure 1.1 - Proportion of the leading causes of death worldwide ............................................ 1 
 
Figure 1.2 – Schematic representation of signaling pathways and factors involved in 
cardiomyocyte differentiation .................................................................................................... 3 
 
Figure 1.3 – Schematic representation of the ultrastructural features of sarcomeres ................ 6 
 
Figure 1.4 – Schematic representation of the cross-bridge cycle ............................................... 7 
 
Figure 2.1 – Schematic representation of the strategies and procedures performed to achieve 
the aims of the thesis .................................................................................................................. 9 
 
Figure 4.1 – hPSC-CMs exhibit cardiac specific markers after 15 days of differentiation. .... 16 
 
Figure 4.2 – hPSC-CMs remain highly glycolytic despite development of metabolic 
machinery during differentiation .............................................................................................. 18 
 
Figure 4.3 - Effect of culture medium composition on central carbon metabolism of hiPSC-
CMs .......................................................................................................................................... 20 
 
Figure 4.4 - Effect of culture media composition on the fluxome of hiPSC-CMs after 
maturation. ................................................................................................................................ 22 
 
Figure 4.5 - Fatty acid rich medium induces lipotoxicity in hiPSC-CMs ................................ 25 
 
 
 
 
List of Tables  
 
Table 1.1 – Comparison of hPSC-CM and adult human cardiomyocytes…………………….5 
 
 
 
 
 
xi 
 
Abbreviation list 
   3-HaCoA 
 
3-hydroxyacyl CoA 
3-KaCoA 
 
3-ketoacyl CoA 
3PG 
 
3-Phosphoglyceric acid 
AcCoA 
ADP 
 
Acetyl-CoA 
Adenosine diphosphate 
AKG 
 
Alpha-ketoglutarate  
ALA 
 
Alanine 
ARG 
 
Arginine 
ASP 
 
Aspartate 
ATP  
 
Adenosine triphosphate  
BSA 
 
Bovine serum albumin  
CIT 
 
Citrate 
CMs 
 
Cardiomyocytes  
CO2 
 
Carbon dioxide 
cTnI 
cTnT 
 
Cardiac muscle troponin I  
Cardiac muscle troponin T 
CYS 
 
Cysteine 
DHAP 
 
Dihydroxyacetone phosphate 
E4P 
 
Erythrose 4-phosphate 
EDTA 
 
Ethylenediaminetetraacetic acid 
eGFP 
 
Enhanced green fluorescent protein  
EMU  
 
Elementary metabolic unit  
END-2 
 
Visceral endoderm-like cell line 
F6P 
 
Fructose-6-phosphate 
FA 
 
Fatty acids 
FAM 
 
Fatty acid medium 
FBP 
 
Fructose-1.6-bisphosphate 
FBS 
 
Fetal bovine serum  
FGF 
 
Fibroblast growth factors  
FUM 
 
Fumarate 
G6P 
 
Glucose-6-phosphate  
GAL 
 
Galactose 
GAP 
 
Glyceraldehyde 3-phosphate 
GC-MS 
 
Gas chromatography–mass spectrometry  
GDH 
 
Glutamate dehydrogenase  
GFAM 
 
Galactose and fatty acid medium 
GLC 
 
Glucose 
GLCM 
 
Glucose rich medium 
GLN 
 
Glutamine 
GLU 
 
Glutamate 
GLUT 
 
Glucose transporter 
GPI 
 
Glucose-6-phosphate isomerase 
xii 
 
GSK3-β 
 
Glycogen synthase kinase-3 beta 
hESC 
 
Human embryonic stem cells  
hESC-CMs 
 
Human embryonic stem cell derived cardiomyocytes  
hiPSC 
 
Human induced pluripotent stem cells  
hiPSC-CMs 
 
Human induced pluripotent stem cell derived cardiomyocytes  
HIS 
 
Histidine 
HPLC 
 
High performance liquid chromatography 
hPSC 
 
Human pluripotent stem cells 
hPSC-CMs 
 
Human pluripotent stem cell derived cardiomyocytes 
IDH 
 
Isocitrate dehydrogenase  
IgG 
 
Immunoglobulin G  
IgM 
 
Immunoglobulin M 
ILE 
 
Isoleucine 
IPA 
 
Ingenuity pathway analysis 
LAC 
 
Lactate 
LACM 
 
Lactate medium 
LDH 
 
Lactate dehydrogenase  
LEU 
 
Leucine 
LYS 
 
Lysine 
MAL 
 
Malate 
MET 
 
Methionine 
MFA 
MID 
 
Metabolic flux analysis  
Mass isotopomer distributions 
NCX 
 
Sodium-calcium exchanger 
NKX-2.5 
 
NK2 homeobox 5   
OA 
 
Oleic acid 
OAA 
 
Oxaloacetate 
P5P 
 
Pentose-5-phosphate  
PA 
 
Palmitic acid 
PBS 
 
Phosphate-buffered saline 
PC 
 
Pyruvate carboxylase  
PDH 
 
Pyruvate dehydrogenase  
PEP 
 
Phosphoenolpyruvate 
PFA 
 
Paraformaldehyde  
PHE 
 
Phenylalanine 
PPP 
 
Pentose phosphate pathway  
PRO 
 
Proline 
PYR 
 
Pyruvate  
qMet 
 
Specific metabolic rate 
RYR 
 
Ryanodine receptor 
S7P 
 
Sedoheptulose-7-phosphate 
SER 
 
Serine 
SERCA 
 
Sarco/endoplasmic reticulum calcium atpase 
SR 
 
Sarcoplasmic reticulum 
xiii 
 
SSEA-4 
sTnI 
 
Stage-specific embryonic antigen-4  
Slow skeletal muscle isoform of troponin I 
SUC 
 
Succinate 
TALDO 
 
Transaldolase 
TCA 
 
Citric acid cycle  
TGF-β 
 
Transcription growth factor β  
THR 
 
Threonine  
TRA-1-60 
 
Human embryonic carcinoma marker antigen  
TYR 
 
Tyrosine 
VAL 
 
Valine  
WB 
 
Washing buffer 
WNT 
 
Wingless-related integration site 
1 
 
1. Introduction 
 
1.1. Stem cell-based therapies for cardiac repair 
 Despite the recent advances in medicine, cardiovascular diseases remain the leading 
cause of death worldwide1 (Fig.1.1). Several cardiovascular diseases, like myocardial 
infarction, are associated with a massive and permanent loss of cardiomyocytes, a non-
proliferative and terminally differentiated cell population2,3. The current pharmacological and 
interventional therapies are not suitable to amend the effects of this cell loss, mainly due to 
the limited regenerative capacity of the myocardium3,4. Even though a subpopulation of 
cardiac stem cells reside in the adult human heart, these are unable to assure a meaningful 
functional recovery, since their renewal rate is only 1% per year5 and a myocardial infarction 
can lead to the loss of approximately one third of the cardiomyocyte population3. On the other 
hand, the proliferation and migration of fibroblasts to the injury site forms scar tissue with 
impaired contractile function that ultimately leads to the progression of cardiac damage6. 
Thus, the only current treatment able to address cardiomyocyte loss and fully restore cardiac 
function is heart transplantation, a procedure limited by the number of compatible organs 
donated1.  
 
 
Figure 1.1 - Proportion of the leading causes of death worldwide. NCDs, noncommunicable diseases. 
Adapted from WHO, 20141.789101112 
 
 
 Stem cell technology presents itself as a great promise in regenerative medicine, 
owing to stem cells ability to proliferate indefinitely, while maintaining an unspecialized 
state, and to differentiate into multiple cell lineages7,8. In fact, numerous groups have reported 
the use of different stem cells types, derived from different sources, to improve cardiac 
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function after injury9-12. Currently, the ESCORT12 clinical trial (phase I) relies on the 
transplant of cardiac progenitors, derived from hESC embedded in a fibrin scaffold for the 
treatment of severe heart failure, leading to symptomatic improvements. Also no 
complications, such as arrhythmias, tumor formation or immunosuppression-related adverse 
events have been reported so far.  
 
1.2. Human pluripotent stem cells 
 Stem cells can be divided into 3 categories, accordingly to their differentiation 
potential. Totipotent cells, corresponding to the zygote, are able to differentiate into all 
embryonic cells as well as extraembryonic tissues13. Pluripotent cells can differentiate into 
cells from all three germ layers, like human embryonic stem cells (hESC) that are obtained 
through isolation of the inner cell mass of blastocysts7,8. Finally, multipotent cells have the 
capacity to differentiate into cells from the same original lineage and can be found in several 
adult tissues such as bone marrow, muscle, brain, adipose tissue13.  
 In 2006 a major breakthrough occurred in the stem cell field, as the reversion of 
somatic cells to a pluripotent state, by overexpression of Oct4, Sox2, Klf4 and c-Myc, was 
reported for the first time in mice14. This finding had such impact in the scientific community 
that the reprogramming of human induced pluripotent stem cells (hiPSC) derived from human 
dermal fibroblast was described shortly after the initial discovery in mice15. hiPSCs possess 
the same pluripotent properties as hESCs, surpassing the ethical concerns associated with the 
use of human embryos, therefore constituting an important alternative to hESCs in clinical 
applications. Furthermore, hiPSCs allow the implementation of an autologous therapy, as they 
can be derived from a patient’s somatic cells, hence circumventing any concern of immune 
rejection15. 
 hPSCs inherent capacity of unlimited self-renewal coupled with efficient directed 
differentiation protocols allow for the large-scale production of specific human cell types, 
which can be used in a wide range of applications, such as developmental biology16, human 
disease modeling17, drug screening17 and regenerative medicine18. Even though animal 
models have been essential in research and clinical use, intrinsic differences with human 
biology limit the reliable use of these models. As such, hPSCs and their differentiated 
progeny hold great potential as a human cellular model17. 
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1.3. Cardiomyocyte differentiation and enrichment 
Differentiation of hPSCs to cardiomyocytes was first reported in 2001 and since then 
distinct approaches have been thoroughly explored, namely differentiation with cells 
cultivated as embryoid bodies19 (three-dimensional aggregates of pluripotent stem cells), co-
culture with inducer END-2 cells20 and guided differentiation strategies (induced by growth 
factors and/or small molecules) in two dimensional monolayers21. Significant improvements 
in efficiency have been achieved through tightly timed, leveled and combined application of 
cardiogenic growth factors or small molecules to manipulate key developmental pathways 
like Wnt, TGF-β, Notch signaling, among others21,22,23 (Fig. 1.2). Animal-derived growth 
factors are expensive and have several safety concerns associated, whereas chemically 
synthesized small molecules display greater stability and facilitated diffusion into multiple 
cell layers, thus decreasing variability and costs, making it the currently preferred 
methodology21,22. 
 
 
Figure 1.2 – Schematic representation of signaling pathways and factors involved in cardiomyocyte 
differentiation. Transcription factors associated with each cell type during cardiomyocyte differentiation are 
presented in the respective boxes. ESC: Embryonic stem cell; iPSC: Induced-pluripotent stem cells. Adapted 
from Kamps et al., 2016 24. 
 
Nowadays most protocols rely on the regulation of the Wnt pathway, which has a biphasic 
role in cardiogenesis, while initial Wnt activation is critical for mesoderm induction it then 
hinders cardiac specification16. Activation of Wnt pathway inhibits glycogen synthase kinase 
3 beta (Gsk3-β) leading to accumulation of b-catenin that is translocated to the nucleus, where 
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it binds to transcription factors that regulate Wnt-responsive genes16. Hence, CHIR99021, a 
small molecule that inhibits Gsk3-β, has been widely used in directed differentiation protocols 
to activate Wnt signaling, whereas subsequent inhibition has been explored with a wide range 
of Wnt antagonist such as IWP4, IWP2, IWR1, Wnt-C59 or XAV93921,23,25. 
 After differentiation, the purity of the final population of hPSC-derived 
cardiomyocytes (hPSC-CMs) is usually low. For example, the first methodology published in 
the literature yielded only 1-5% of beating cells19. Addition of growth factors and adaptation 
to monolayer-based directed differentiation techniques enhanced the yield to >30%18, 
however this approach still presents significant variability between cell lines and 
experiments26. Temporal modulation of Wnt signaling has shown great progress towards the 
generation of hPSC-CMs, with high purity (80-98% of cTnT-expressing cardiomyocytes), 
obtained from both hESC and hiPSC lines21. 
 The persistence of undifferentiated hPSC is a great safety concern for clinical 
applications, as the tumorigenic potential of hPSC may lead to the formation of malignant 
tumors when transplanted into the host27. Thus, throughout the years several strategies have 
been explored to remove these cell contaminants and improve the purity of hPSC-CMs. For 
instance, the use of Percoll gradients28, Flow Activated Cell Sorting for specific surface 
markers29 and for cells incubated with mitochondrial dyes30 or molecular beacons31 have 
already been reported. One elegant and more efficient approach is to culture hPSC-CM in 
medium containing lactate (LAC) instead of glucose (GLC)32. Since hPSC and fibroblasts 
rely highly on glucose, only cardiomyocytes, which can use both metabolites, survive when 
cultured in this medium32.   
 
 
1.4. Maturation of hPSC-CMs 
 Notwithstanding the progress made in improving differentiation protocols, the final 
population of hPSC-CM obtained remains immature with a fetal-like phenotype, whether in 
terms of structure33, gene expression34, metabolism35, contractile function or 
electrophysiology36 (Table 1.1). Thus, immaturity is currently a critical obstacle hampering 
the potential of hPSC-CMs in cell therapy, drug discovery, toxicity testing and cardiac disease 
modeling37.  
 A wide range of strategies to improve maturation of hPSC-CM have been explored so 
far. These include the overexpression of microRNAs that regulate cardiac development38; 
addition of chemical supplements to the culture medium, like the growth hormone T339; and 
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culture of hPSC-CMs in organic or synthetic scaffolds coupled with cyclic stretching40 and/or 
electrical cues41, which have been reported to improve the expression of cardiac markers, cell 
morphology and ultrastructure, respiratory capacity and contractile kinetics. Nonetheless a 
mature phenotype reminiscent of fully recapitulated adult cardiomyocytes has yet to be 
achieved. 
 
Table 1.1 – Comparison of hPSC-CM and adult human cardiomyocytes. Adapted from White et al., 2016 37. 
 
 
1.5. Cardiomyocyte structure and contraction 
 Adult cardiomyocytes have an elongated rod-like shape and present a highly organized 
internal structure composed of numerous parallel myofibrils, which consist of longitudinal 
repetitions of sarcomeres, the functional units of muscle42. Cardiomyocyte shape and 
sarcomere alignment have functional implications in excitation-contraction coupling and in 
the generation of contractile force43. During pathogenic hypertrophy cardiomyocytes adopt a 
rounder shape and display disorganized sarcomeres44, as such pathogenic growth has been 
reported to accompany several forms of heart disease45. In contrast, physiological 
hypertrophy, which occurs during normal heart development, the addition of new sarcomeric 
units is in longitudinal series or parallel to pre-existing ones thus maintaining sarcomere 
alignment and cardiomyocyte shape44. 
 The sarcomere is composed of a complex assembly of both thick and thin filaments, 
the former consists of myosin while the latter includes actin, troponin and tropomyosin. Each 
sarcomere is delimited at either end by a Z-disc, which is included in the I-band, composed by 
thin filaments that extend in both directions (Fig. 1.3). The A-band comprises the portion of 
the sarcomere where thick and thin filaments overlay, while the H-zone in the center of the A-
band contains only thick filaments. In the middle of the H-zone is the M-line that corresponds 
to the center of the sarcomere46. 
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Figure 1.3 – Schematic representation of the ultrastructural features of sarcomeres. Adapted from Feric et 
al., 201547. 
 
 
 During an action potential of adult cardiomyocytes, membrane depolarization activates 
voltage gated calcium (Ca2+) channels allowing the entry of Ca2+ into the cell. This triggers 
the release of Ca2+ from the sarcoplasmic reticulum in a positive feedback process, the Ca2+-
induced-Ca2+ release48. The binding of Ca2+ to troponin induces a conformational change and 
displaces tropomyosin, thereby exposing the binding sites of actin to which energized myosin 
heads will attach forming cross-bridges49 (Fig. 1.4). Consequent release of ADP and Pi 
(inorganic phosphate) bend the myosin heads, which switch to a low energy state, pulling the 
actin filaments toward the center of the sarcomere (M-line). Binding of ATP to the myosin 
heads lead to cross-bridge detachment, and ATP hydrolysis restores myosin to the energized 
state and raised conformation. Since thin filaments are anchored to the Z-discs, this process 
leads to sarcomere shortening, thus resulting in cell contraction46. During relaxation, Ca2+ is 
pumped back into the sarcoplasmic reticulum and to a lesser degree extruded from the cell, so 
as to return the cell to resting Ca2+ levels. As Ca2+ detaches from troponin, this protein returns 
to the initial conformation simultaneously moving tropomyosin to cover the actin binding 
sites. This blocks myosin from forming cross-bridges, therefore a new cycle of contraction is 
only possible after a new stimuli48.   
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Figure 1.4 – Schematic representation of the cross-bridge cycle. Adapted from Martini et al., 201150. 
 
 
1.6. Metabolic dynamics during heart development 
 The incessant contractile function of the human heart, along with cardiomyocytes 
minimal ability to store high-energy phosphates, results in a high metabolic demand requiring 
a continuous high production rate of ATP to sustain proper cell function35,51. However, the 
metabolic profile of the fetal heart is not compliant with this demand, since at this point of 
development cardiomyocytes are highly dependent on glycolysis, and to a lesser extent lactate 
oxidation, to produce ATP35. Hence, during heart development, a metabolic shift occurs from 
primarily glycolytic to an oxidative metabolism, where the adult heart relies mainly on 
mitochondrial fatty acids (FA) oxidation to ensure ATP production35. Nevertheless, 
cardiomyocytes retain metabolic plasticity to use other substrates (glucose, lactate, amino 
acids, ketone), depending on their availability35,52.   
 In vitro, hPSC-CMs rely mainly on glycolysis when cultured in media containing 
glucose, even if present at low concentrations in media with other substrates available32,53. In 
the absence of glucose, hPSC-CMs were able to metabolize other substrates to support cell 
function32,53. Notably, galactose (GAL) alone or in combination with fatty acids was able to 
induce the metabolic switch in hiPSC-CMs, as well as an increase in mitochondrial reserve 
and maximum respiratory capacity53. Even so, a link between the metabolic shift and 
maturation of hPSC-CM in vitro has not been established.  
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 1.7. Metabolic Flux Analysis 
 Metabolic flux analysis (MFA) is currently the preferred technique to obtain 
quantitative data about in vivo metabolism54. Initially, MFA studies relied on metabolite 
balances within an assumed network stoichiometry, where external rate measurements 
provided constraints to determine intracellular fluxes. However this approach could not 
distinguish fluxes of parallel pathways (e.g. glycolysis vs. pentose phosphate pathway), 
reversible reactions, and cyclic pathways. A shortcoming overcome by combining MFA with 
measurement of the metabolic conversion of stable isotopic tracers, like 13C, by mass 
spectrometry or nuclear magnetic resonance55. Thus, providing additional independent 
constraints for flux estimation greatly improving quantitative resolution of metabolic flux 
distributions, at the expense of increased experimental and computational complexity. 
Currently, the elementary metabolic unit (EMU) method is considered the most advanced and 
efficient computational approach for simulating isotopic labeling distributions56.  
 In summary, nonstationary 13C-MFA relies on computational simulation to estimate a 
set of feasible intracellular metabolic fluxes that minimize the variance-weighted sum of 
squared residuals between the predicted and measured transient 13C-labeling data and 
extracellular rate measurements54.  
 Despite the increasing role of nonstationary 13C-MFA in metabolism studies of a wide 
range of biological systems54,57,58, a metabolic network model of hiPSC-CMs has yet to be 
explored. 
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2. Aim of the thesis 
 
 The main aim of this thesis was to evaluate if altering the composition of hPSC-CM 
culture medium to mimic substrate availability during cardiac development, would promote 
hPSC-CMs maturation in vitro.  
 Based on a recently developed methodology for the directed differentiation of hPSC 
into cardiomyocytes in two dimensional monolayer culture systems, the first objective of this 
thesis was to perform a proteomic characterization of two distinct cell populations: pluripotent 
stem cells (hPSC) and cardiomyocytes (hPSC-CM). 
 After differentiation, hiPSC-CMs were cultured in glucose depleted medium 
supplemented with either i) fatty acids (FAM), ii) galactose and fatty acids (GFAM) or iii) 
lactate during the first 10 days followed by a switch to galactose and fatty acids 
(LACM&GFAM), using the standard glucose rich hiPSC-CMs medium (GLCM) as reference 
(Fig. 2.1). To study the impact of distinct carbon sources in metabolic profile and maturation 
status of hiPSC-CMs, metabolomics methodologies such as HPLC and GC-MS were used and 
structural analysis was performed throughout 20 days of culture. Additionally, parallel 
labeling experiments and 13C-MFA were used for estimation of intracellular flux distributions 
(fluxome). 
 
 
 
Figure 2.1 – Schematic representation of the strategies and procedures performed to achieve the aims of 
the thesis. 
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3. Materials and Methods 
 
3.1. Cell Culture 
3.1.1. hPSC maintenance and differentiation to cardiomyocytes  
 In this study two hPSC cell lines were used, the hiPSC line DF19-9-11T.H from 
WiCell as well as the cardiac fluorescent reporter cell line hESC-NKX2.5(eGFP/w)59 kindly 
provided by Dr. David Elliot (Murdoch Children Research Institute). In this reporter line, 
eGFP was targeted to the genomic locus of the cardiac transcription factor NKX2.5, therefore 
being expressed upon differentiation towards the cardiac lineage, with further increase in 
functional cardiomyocytes59. hPSCs were cultured on Matrigel® (Corning) coated plates in 
mTESR1 medium (STEMCELL Technologies) until reaching 80%-90% confluency at which 
point differentiation to cardiomyocytes was induced as previously described60. Briefly, this 
directed differentiation protocol involves the use of RPMI+B27 medium (Invitrogen) and 
serial application of Activin A (PeproTech), CHIR99021 (Biogen Cientifica S.L.), Ascorbic 
Acid (Sigma-Aldrich) and IWR1 (Sigma-Aldrich) in bidimensional monolayer culture 
conditions. Cells were cultured at 37°C, in a humidified atmosphere of 5% CO2.  
 
3.1.2. hiPSC-CM maturation 
 After 15 days of differentiation, hiPSC-CMs were cultured for further 20 days in four 
different culture media formulations (Fig. 2.1): i) GLCM (Glucose Medium): standard hiPSC-
CM medium (RPMI+B27); ii) FAM (Fatty Acid Medium): RPMI without GLC supplemented 
with B27, 1mM glutamine (GLN) (Alfagene), 100µM oleic acid (OA), 50µM palmitic acid 
(PA) (both from Sigma-Aldrich);  iii) GFAM (Galactose and Fatty Acid Medium): RPMI 
without GLC supplemented with B27, 1mM GLN, 10mM galactose (Sigma-Aldrich), 100µM 
OA and 50µM PA; and iv) LACM&GFAM: 10 days in RPMI without GLC supplemented 
with B27, 1mM GLN and 4mM sodium L-lactate (Sigma-Aldrich) (Lactate Medium) and 
another 10 days in  GFAM (Figure 1A). At day 25 (d25) and 35 (d35), hiPSC-CMs were 
collected for metabolic and structural analysis. 
 
3.1.3. Cell concentration and viability 
 Cell concentration and viability were determined by cell counting in a Fuchs–
Rosenthal haemocytometer (Brand) using the trypan blue (Sigma-Aldrich) exclusion method 
(0.1% (v/v) in PBS). 
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3.2. Characterization of hPSC-CMs 
3.2.1. Flow cytometry analysis  
 Cells were dissociated with TrypLETMSelect (Invitrogen) and ressuspended in washing 
buffer (WB) solution (5% (v/v) FBS in PBS). After two washing steps with WB, cells were 
incubated with primary antibody for 1 h at 4°C followed by another set of 2 washing steps 
with WB. For determination of intracellular markers the BD Cytofix/Cytoperm™ kit (BD 
Biosciences) was used accordingly to the manufacturer’s instructions. Cells were incubated 
with secondary antibody for 30 min at 4°C. Finally, cells were suspended in WB and analyzed 
in a flow cytometer (CyFlow® space, Partec GmbH) registering at least ten thousand events 
per analysis. Primary antibodies used: Tra-1-60, SSEA-4, isotype control antibodies (1:10, all 
Santa Cruz Biotechnology) and cardiac Troponin T (cTnT) (1:20, Thermoscientific). 
Secondary antibodies used were: goat anti-mouse IgM-AlexaFluor488 and goat anti-mouse 
IgG-AlexaFluor488 (1:200, all from Invitrogen) 
 
3.2.2. Qualitative total proteome analysis 
 Cell pellets from d0 and d15 of differentiation from both cell lines were lysed in 
50mM Tris, 5mM EDTA, 150mM NaCl, 1% Triton X-100 (all from Sigma-Aldrich)  and 1X 
Protease Inhibitor (Roche), for 45 minutes at 4ºC. Centrifuged at 15000g for 15 minutes at 
4ºC and collected the supernatant. Protein concentration was assessed by microBCA 
(Thermoscientific) following manufacturer’s instructions. Normalized quantities of protein 
were reduced, alkylated and digested overnight at 37 ⁰C with trypsin (Promega, 1.6 ng/µl). 
The digested samples were lyophilized using a SpeedVac centrifuge (ThermoSavant) and 
dissolved in 12 μl of water with 0.1% formic acid. An Eksigent LC 4500 coupled to 
TripleTOF 6600 (Sciex) equipment was used to analyze the samples. Two biological 
replicates per time point were run in technical triplicate.  Data was acquired with the Analyst 
software TF 1.7 (Sciex) and analyzed using the ProteinPilot software (Sciex). The complete 
data set of proteins identified was further analyzed with Ingenuity Pathway Analysis (IPA) 
software (Qiagen)61. Statistically significant over-representation of given biological functions 
and canonical pathways were identified based on a probability score, p-value. This p-value is 
calculated by considering the total number of proteins know to be associated with a 
determined function or pathway, and their representation in the selected dataset. IPA’s 
calculated score was displayed as the negative log of p-value. 
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3.3. Nonstationary 13C-Metabolic Flux Analysis 
3.3.1. Metabolite analysis 
 Glutamine (GLN), glutamate (GLU), glucose (GLC) and lactate (LAC) concentrations 
from culture supernatants were measured using YSI 7100MBS (YSI Incorporated). 
 Enzymatic assay kits were used to quantify ammonia (NZYTech), galactose and fatty acids 
(both from Abcam). Amino acid concentration was determined by HPLC using the Waters 
AcQ.Tag Amino Acid Analysis Method (Waters), as described elsewhere62. The specific 
metabolic rates (qMet, expressed in μmol.h-1.106 cell-1) were calculated using the equation: 
qMet = ΔMet/(Δt  Xv), where ΔMet (mol/L) is the variation of metabolite concentration 
during the time period Δt (h), and Xv (cell/L) the average of cell concentration during the 
same time period. 
 
3.3.2. Isotopic tracer experiments and GC-MS analysis 
 For the parallel isotopic labelling experiments the following isotopic tracers were 
used: [1,2-13C]Glucose; [U-13C]Glutamine; [3-13C]Sodium L-Lactate; [U-13C]D-Galactose 
(all from Cambridge Isotope Laboratories) and [18-13C]Oleic Acid; [16-13C]Palmitic Acid 
(from Sigma-Aldrich). Only one isotopic tracer was used at a time to allow monitoring of the 
incorporation of each tracer. Label incorporation was characterized 24 and 48h after label 
addition. At the chosen time points, culture supernatants were collected and each plate was 
completely dipped in liquid N2. After addition of 1mL of 50% (v/v) ice-cold acetonitrile 
(ThermoFisher) to each well, cells were scrapped and collected. Cell extracts were 
centrifuged at 15000 g for 10 min at 4°C, and collected supernatants were lyophilized 
overnight using a SpeedVac centrifuge (ThermoSavant). Amino acids, lactate and TCA 
intermediates were derivatized with N-methyl-N-tert-butyldimethylsilyl-trifluoroacetamine 
(MBDSTFA, Aldric, DE) as reported elsewhere58. 
 Metabolites were analyzed in a QP2010 mass spectrometer (Shimadzu, Japan) in the 
EI mode (70 eV) with a HP-5 MS column (Agilent Technologies). The obtained spectra were 
analyzed and integrated using GC-MS Solution software version 2.50 SU1 (Shimadzu, 
Japan). Mass Isotopomer Distributions (MID) were calculated after spectra integration and 
corrected for natural isotope abundance. The contribution of each 13C-labeled substrate to 
TCA cycle intermediates was determined as the percentage of tracer incorporation in citrate, 
fumarate and malate.  
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3.3.3. Metabolic network and nonstationary 13C-MFA 
 Nonstationary 13C-MFA of parallel labelling experiments was performed using the 
software package INCA63, which automatically generates and simulates mass and material 
balance equations from a user-defined metabolic network structure and experimental datasets. 
At least 10 restarts with random initial values for the parameters (intracellular fluxes and 
pools) were performed to find a global optimum.  
 
3.3.4. ATP production 
 ATP production was estimated by taking into account referenced ATP production in 
glycolysis, TCA and b-oxidation by each substrate64 and respective flux values determined in 
nonstationary 13C-MFA.  
 
 
3.4. Assessment of hiPSC-CM structure  
3.4.1. Immunofluorescence microscopy 
 Cells were washed with DPBS and fixed in 4% (w/v) PFA in DPBS solution for 15 
min. After being permeabilized and blocked with 5% (v/v) FBS, 1% (w/v) BSA, 0.3% (v/v) 
Triton X-100 in DPBS for 1h, at room temperature (20-25°C), cells were incubated with 
primary antibody, troponin I (1:100, Millipore), diluted in 1% (w/v) BSA, 0.1% (w/v) TX-100 
in PBS overnight at 4°C. Afterwards, cells were washed in DPBS and incubated with 
secondary antibody, Alexa Fluor 594 goat anti-mouse IgG (1:500, Invitrogen), in the dark for 
1h at room temperature (20-25°C). Cell nuclei were counterstained with Hoechst 33342 
nucleic acid dye (1:1000, Thermo Scientific). Representative images were taken using an 
inverted fluorescence microscope (DMI 6000, Leica). 
 
3.4.2. Cell morphology 
 Cell area, circularity index and aspect ratio were determined in ImageJ software 
(National Institutes of Health) using standard analysis plugins. For each condition, at least 70 
cells were evaluated. 
 
3.4.3. Measurement of mitochondrial membrane potential  
 Differences in mitochondrial membrane potential, were evaluated using Mitoview™ 
633 (Biotium) following manufacturer's instructions. Briefly, after incubation with the dye for 
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1 h, fluorescence was measured in a microwell plate fluorescence reader, Infinite 200 PRO 
NanoQuant (TECAN).  
 
3.4.4. Lipid droplets content 
 Lipid droplet content was assessed using the Lipid Droplets Fluorescence Assay Kit 
(Cayman), according to the manufacturer’s instructions. Fluorescence was quantified in a 
microwell plate reader, Infinite 200 PRO NanoQuant (TECAN).  
 
 
3.5. Statistical analysis 
 Statistical analysis was performed using GraphPad Prism Software version 5 
(GraphPad Software). Values are represented as mean±SD of independent measurements or 
assays (at least n=3 replicates were considered). Statistical significance was evaluated using 
Student's t test with Welch's correction. Values of p<0.05 were considered statistically 
significant. 
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4. Results and Discussion 
 
4.1. hPSC-CMs remain highly glycolytic regardless of metabolic development during 
differentiation  
Starting with a protocol previously implemented in the lab for the directed 
differentiation of hPSC-CMs in two dimensional monolayers60, cells’ proteome 
characterization was pursued through mass spectrometry tools. Two hPSC lines were used: 1 
hiPSC line (DF19-9-11T.H) and 1 hESC line (cardiac fluorescent reporter cell line hESC-
NKX2.5(eGFP/w))59. 
Cell population was characterized by flow cytometry before (hPSC, d0) and 15 days 
after inducing cardiomyocyte differentiation (hPSC-CM, d15). At d0, pluripotency markers 
SSEA4 and TRA-1-60 were highly expressed (>90%) in both hiPSC and hESC lines, 
confirming the maintenance of pluripotency throughout cell expansion in monolayer culture 
(Fig. 4.1 A). The efficiency of cardiomyocyte differentiation was evaluated by analyzing the 
percentage of cTnT and eGFP-expressing cells in hiPSC and hESC, respectively, at d15. 
Results showed that 94.0±4.7% and 85.7±5.5% of cTnT and eGFP-expressing cells in hiPSC 
and hESC, respectively, were attained (Fig. 4.1 B and C), which confirms the high efficiency 
of temporal modulation of Wnt signaling in directing cardiomyocyte differentiation from both 
hESC and hiPSC lines21. Furthermore, hPSC-CMs start displaying spontaneous contraction at 
day 6 of differentiation, maintaining this automaticity throughout culture time.  
Cell pellets were collected from hPSC populations at both time points (d0 and d15) for 
qualitative total proteome analysis. From the total proteins identified, 40-50% are exclusive to 
either hPSC (d0) or hPSC-CM (d15) (Fig. 4.1 D and E), revealing an extended degree of 
variation in the proteome profile during differentiation to a cardiac lineage. Total proteome 
data was analyzed with IPA for predictive insights of biological functions and canonical 
pathways relevant for each sample time point. This software analyzes large datasets to find 
the most significant functions and pathways based on a calculated probability score, 
attributing a p-value to each annotation61. Analysis of the proteomic profile identified two 
clearly distinct cell populations, in this case hPSC and hPSC-CMs. In hPSC there is a 
significant over-representation of proteins associated with proliferation and cell cycle (Fig. 
4.1 F), which were not observed in hPSC-CMs. Even though previous reports have termed 
cardiomyocytes as non-proliferative cells, by measurement of the chemiluminescence of 
BrdU (5-bromo-2′-deoxyuridine) incorporation during DNA synthesis4, this data 
demonstrates 
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Figure 4.1 – hPSC-CMs exhibit cardiac specific markers after 15 days of differentiation. Percentage of 
positive cells expressing: pluripotency markers at d0 (A) and cardiac markers at d15 (B) and (C); was assessed 
by flow cytometry. Typical cTnT+ and Nkx2.5-eGFP+ populations in cells produced from the applied 
differentiation protocol are represented in (B) and (C), respectively. Grey histograms represent isotype control. 
Venn diagram illustrating the overlap of all proteins identified by qualitative proteome analysis, at d0 and d15 in 
(D) hiPSC and (E) hESC. Enrichment in biological functions determined with IPA at (F) d0 and (G) d15. IPA’s 
calculated score is displayed as the negative log of p-value, the cut-off considered is 1.3. (H) Schematic 
representation of the link between calcium signaling and muscle contraction at d15, adapted from IPA. Grey 
depicts proteins present in the selected dataset whereas in white are proteins involved in these processes but not 
present in the data. Data represented as mean±SD. ns, not significant. 
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demonstrates that the difference in the proliferative phenotype of pluripotent stem cells and 
cardiomyocytes is evident even at the proteome level. After 15 days of differentiation there is 
an enrichment of cardiac related biological functions, specifically cardiomyocyte morphology, 
sarcomere organization, contraction and calcium signaling pathway (Fig. 4.1 G), further 
reinforcing the data obtained from flow cytometry (Fig. 4.1 B and C) and the assumption that 
the methodology applied was successful in directing the differentiation of both hiPSC and 
hESC into cardiomyocytes. 
 A closer look into the proteins identified that are involved in the calcium signaling 
pathway revealed the presence of the main calcium channels that regulate muscle contraction 
in cell populations from d15 (Fig. 4.1 H). For example: RYR, ryanodine receptor that upon 
depolarization releases Ca2+ from the sarcoplasmic reticulum (SR), inducing muscle 
contraction65; SERCA the sarco/endoplasmic reticulum calcium ATPase that actively 
transports Ca2+ from the cytoplasm into the SR65; and NCX, the Na+-Ca2+ exchanger that 
during relaxation prevents overloading of intracellular stores by exporting Ca2+ from the 
cell66. Moreover, all of the myofilaments essential for cardiac contraction were present in 
proteomics data from both cell lines at d15 (Fig. 4.1 H). Troponin is a heterotrimeric protein 
complex composed of troponin-I, troponin-T and troponin-C49. Binding of Ca2+ to the latter 
triggers a conformational shift in the complex formed by troponin and tropomyosin, exposing 
α-actin for interaction with myosin ultimately resulting in a contraction49. Also of note was 
the identification of cTnI, the adult cardiac isoform of troponin I, in both hPSC-CMs lines. 
After birth this adult isoform completely and irreversibly replaces the fetal isoform sTnI67. 
Although the sTnI isoform was still identified in hPSC-CMs, the identification of cTnI hints 
that the differentiation protocol applied was able to, at least in part, mimic heart development 
until this transitioning phase.  
 Proteomic analysis also revealed an overall enrichment in metabolic pathways in 
hPSC-CMs when compared to hPSC. A distinct over-representation of proteins related to 
oxidative phosphorylation, TCA cycle, glycolysis and fatty acid β-oxidation pathways was 
observed in hPSC-CMs (Fig. 4.2 A). While these results may allude to an increased oxidative 
metabolism, that is not the case seeing as metabolic results suggest that both hPSC and hPSC-
CMs rely mainly on anaerobic glycolysis32. Analysis of the ratio between lactate production 
and glucose consumption confirms maintenance of the glycolytic profile in both cell 
populations (YLAC/GLC=1.74 in hPSC vs 1.76 in hPSC-CMs) (Fig. 4.2 B). In anaerobic 
glycolysis, glucose is channeled for lactate production, thus this ratio theoretically equals 2 64. 
A pondered evaluation of both proteomics and metabolite data suggests that although hPSC-
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CMs remain highly glycolytic, the increased identification of proteins involved in oxidative 
metabolic pathways after 15 days of differentiation reflects an overall development in terms 
of metabolic machinery during cardiomyocyte differentiation. This suggests a relation 
between hPSC-CMs metabolic profile and the carbon source available in the medium. 
Therefore further metabolic studies were pursued to investigate this possible link, using only 
the hiPSC cell line.  
Overall, resource to mass spectrometry tools allowed for a proteomic characterization 
of both hPSC and the final population of hPSC-CMs obtained, revealing an enrichment in 
cardiac markers and metabolic machinery in hPSC-CMs. Therefore this tool revealed itself 
valuable in complementing other analytical tools widely reported in the literature to 
characterize hPSC-CMs21-23. A drawback of the methodology applied herein lies with the fact 
that this proteome analysis is not quantitative. This limits additional conclusions particularly 
from the set of proteins present in both hPSC and hPSC-CMs, since a quantitative analysis 
could expose differences in proteins up- or down-regulated. To surpass this limitation a 
quantitative approach, like SWATH68, could be used in future proteome analysis to elucidate 
the evolution of the proteomic profile throughout the directed differentiation of hPSC-CMs.  
 
 
 
 
Figure 4.2 – hPSC-CMs remain highly glycolytic despite development of metabolic machinery during 
differentiation. (A) Heatmap depicting top metabolic canonical pathways determined by IPA, the calculated 
score is displayed as the negative log of p-value, and the cut-off considered is 1.3. (B) Ratio between lactate 
production and glucose consumption, yLAC/GLC. Data represented as mean±SD. ns, not significant. 
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4.2. hiPSC-CMs shift to an oxidative metabolism in the absence of glucose 
After 15 days of differentiation, hiPSC-CMs were maintained for an additional 20 
days (i.e. from day 15 to 35) in distinct glucose depleted culture media besides the standard 
glucose rich medium used as reference, as described above (section 2, Fig. 2.1). Samples were 
collected at day 15, 25 and 35 (hereafter designated as d15, d25, d35) of total culture time 
(Fig. 2.1). Analysis of the metabolic profile of the main substrates available in each media 
throughout culture, confirms that hiPSC-CMs maintained in glucose rich medium (GLCM) 
remain highly dependent on anaerobic glycolysis, as denoted by the high production rate of 
lactate at d35 (Fig. 4.3 A). However, in the absence of glucose, hiPSC-CMs were able to 
metabolize other substrates namely lactate, fatty acids and galactose (Fig. 4.3A), showing 
remarkable metabolic plasticity as previously described for human adult cardiomyocytes35.  
Furthermore, a shift occurs from a metabolism highly dependent on anaerobic glycolysis, 
since there is no production of lactate in either FAM, GFAM or LACM&GFAM media. 
Hence, the overall development of metabolic machinery during differentiation, revealed by 
proteomics analysis (Fig. 4.2), may reflect a developmental adaptation of hiPSC-CMs to the 
consumption of distinct carbon sources and consequent metabolization through oxidative 
pathways. Additionally, these results suggest that when the main substrate available in the 
media is glucose, the preferred consumption of this substrate53 restricts hiPSC-CMs 
metabolism to a glycolytic profile.  
Culture of hiPSC-CMs with uniformly 13C-labelled versions of the corresponding 
substrates allowed the analysis of the incorporation of 13C into lactate and TCA cycle 
intermediates (citrate, fumarate and malate). hiPSC-CMs maintained in GLCM showed no 
improvements in oxidative capacity from d15 to d35, seeing as around 90% of lactate derived 
from [1,2-13C]Glc, upon 48h incubation, and the fraction of intracellular pools of  TCA cycle 
intermediates remained unchanged (Fig. 4.3 B). 
 At d15 the switch to FAM showed that although the switch to reliance on fatty acid 
metabolization was immediate, it occurred in a low degree with only 18% of the labeled 
fraction of TCA cycle intermediates deriving from [U-13C]PA and [U-13C]OA at d15 (Fig. 4.3 
C). The remaining 82% derived from [U-13C]Gln, which suggests an important contribution 
of glutaminolysis to support TCA cycle anaplerosis. However, at d25 the contribution from 
fatty acids to TCA cycle increased to 35%, revealing an adaptation to fatty acid consumption. 
In the presence of galactose (GFAM), the incorporation of [U-13C]Gln decreased to 38%, in 
favor of [U-13C]Gal incorporation in TCA cycle (Fig. 4.3 D). Moreover hiPSC-CMs showed 
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an adaptation to fatty acid consumption similar to that observed in FAM, as the overall 
contribution to labeled TCA cycle pools increased from 19% at d15 to 36% at d35. 
 
 
Figure 4.3 - Effect of culture medium composition on central carbon metabolism of hiPSC-CMs. (A) 
Heatmap image of metabolome data illustrating specific consumption (blue) and production (red) rates of 
metabolites (qMET; nmol/h/106cell). (B) Percentage of labelled M2 isotopomers from [1,2-13C]Glc in lactate and 
TCA intermediates (citrate, fumarate, malate. (C-E) Pie charts reflecting the contribution of the main substrates 
present in each culture medium, for TCA cycle intermediates pools, at different timepoints. The percentages 
were determined based on the incorporation of each labelled substrate in citrate, fumarate and malate after 48h of 
incubation.  
 
 For hiPSC-CMs cultured in LACM&GFAM, the incorporation of fatty acids in TCA 
intermediates was similar at both d25 and d35 (approximately 30%) (Fig. 4.3 E). Since 
LACM&GFAM resembles substrate availability during heart development35, these data could 
reflect what happens in vivo, as initial reliance in lactate oxidation may precondition hiPSC-
CMs, allowing for a better adaptation to fatty acid metabolization upon initial exposure to this 
substrate. Like in GFAM, in LACM&GFAM condition, there is also a decrease in glutamine 
contribution concomitant with increased incorporation of [U-13C]Gal, although to a lower 
degree, highlighting the increased role of fatty acids and galactose as fuel of TCA cycle in 
detriment of glutamine. 
C) 
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 In order to comprehensively characterize fluxome changes of hiPSC-CMs cultured in 
distinct media, uptake and production rates along with 13C incorporation data from parallel 
labelling experiments were integrated in a metabolic network model using nonstationary 
MFA54. At first glance, there is a remarkable difference between flux maps from GLCM and 
GFAM conditions at d35. In GLCM, hiPSC-CMs showed a highly glycolytic metabolism 
while in GFAM there is a higher reliance in TCA cycle along with a pronounced distribution 
of fluxes in other pathways like glycolysis and β-oxidation (Fig. 4.4 A and B). Importantly, 
hiPSC-CMs cultured in LACM&GFAM and GFAM had similar fluxomes at d35 (data not 
shown). Combination of fluxome and metabolome analyses reported herein with the 
transcriptomic data obtained from parallel experiments developed in the lab (Fig. S1), 
revealed that changes in metabolism were accompanied by alterations in metabolic gene 
expression. 
 In GFAM glycolytic fluxes decreased around 9-fold and fluxes of TCA cycle 
increased over 6-fold comparatively to GLCM. The glycolytic profile of GLCM is supported 
by up-regulation in the gene expression of key enzymes like SLC2A1, HK1/2 and ENO3 (Fig. 
S1), moreover virtually all of the cytosolic pyruvate is diverted to lactate secretion (491.4 in 
GLCM vs 0.0 nmol/(106 cells × h) in GFAM). In contrast, in GFAM, pyruvate is channeled to 
the mitochondria where it enters TCA cycle by conversion to Acetyl-CoA (67.2 in GFAM vs 
5.6 nmol/(106 cells × h) in GLCM), also in this condition most of the enzymes involved in the 
TCA cycle are up-regulated (Fig. S1). Culture of different cell types, like muscle and cancer 
cells, in medium containing galactose has proved to enhance oxidative metabolism53,69. 
Despite relying in the same family of GLUT transporters, the uptake rate of galactose is 
markedly lower than that of glucose, due to low affinity of the transporters to galactose70. 
This results in a steep decrease in glycolytic flux, and consequent reduction in ATP 
production from anaerobic glycolysis, therefore cells increase their reliance on oxidative 
phosphorylation to maintain ATP levels69.  
Another important feature of GFAM metabolism, that is negligible in GLCM, is the 
increased oxidation of fatty acids (10.3 in GFAM vs 0.0 nmol/(106 cells × h) in GLCM) 
concomitant with a higher expression of enzymes involved in β-oxidation (Fig. S1), thus 
revealing an adaptation, also at the gene expression level, to more efficiently consume fatty 
acids. 
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Figure 4.4 - Effect of culture media composition on the fluxome of hiPSC-CMs after maturation. 
Metabolic flux maps highlighting central carbon metabolism at d35 of hiPSC-CMs cultured in GLCM (A) and 
GFAM (B). Flux maps were determined using nonstationary 13C-MFA analysis. Arrow thickness reflects flux 
values in units of nmol/h/106cell (see Table S1 for exact flux values). Up-regulated and down-regulated genes 
encoding metabolic enzymes are demarked in red and green, respectively. Genes were considered enriched based 
on a fold difference in expression (FC) ≥1.3 when compared with d15 (see Figure S1 for heatmap of FC from all 
culture conditions). Estimation of total ATP production and contribution of each metabolic pathway in GLCM 
(C) and GFAM (D). (E) Fold increase in mitochondrial membrane potential assessed at d35 by the increase in 
fluorescence intensity of the mitochondria specific dye, Mitoview. Fluorescence values were normalized for the 
values obtained in cells cultivated in GLCM. Data represented as mean±SD. *p<0.05; ns, not significant. 
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Even though flux through the Pentose Phosphate Pathway (PPP) is similar in GLCM 
and GFAM, it seems to have a greater relevance in the latter since approximately 70% of the 
glycolytic flux is diverted to PPP, contrasting with 13% in GLCM (Fig. 4.4 A and B). PPP is 
one of the main antioxidant cellular defense systems in cells and the higher estimated fluxes 
in GFAM may reflect an adaptation to prevent detrimental effects of increased production of 
free radicals promoted by the metabolic transition to aerobic respiration and oxidative 
phosphorilation71. Nonetheless, up-regulation of GPI and TALDO1 (Fig. S1) suggests that 
galactose was consumed through the glycolytic pathway (Fig. 4A and B). 
 The remodeling in metabolic profile is also evident in terms of estimated ATP 
production, which was determined by taking into account flux values estimated in 
nonstationary 13C-MFA. In GLCM, 71% of total ATP produced derived from glycolysis, 
while in GFAM glycolysis corresponds to only 3% with the remaining 97% resulting from 
oxidative metabolism (Fig. 4.4 C and D). This improved reliance on oxidative metabolism 
increased 2.6-fold the total of ATP production in GFAM (1759 in GFAM vs 687 mmol/h in 
GLCM). Therefore this improvement may reflect a metabolic adaptation to comply with the 
increased energetic demand placed by hiPSC-CMs contractile function, as both cross-bridge 
and Ca2+ cycling are ATP-dependent processes48.  
 To evaluate if the switch to an oxidative metabolism had any effect in mitochondria, 
cells were incubated with Mitoview, a fluorescent probe that acts as a reporter of 
mitochondrial membrane potential, which is crucial for maintaining ATP production72. 
Quantification of fluorescence intensity revealed a significant increase in membrane potential 
in both GFAM and LACM&GFAM comparatively to GLCM (Fig. 4.4 E), which indicates 
that in these conditions hiPSC-CMs displayed improved mitochondrial functionality. So, 
altogether this data indicates that hiPSC-CMs switch to an adult-like oxidative metabolism 
when cultured in GFAM and LACM&GFAM. 
 
 
4.3. Supplementation of fatty acid medium with galactose prevents lipotoxicity  
 When cultured in FAM, hiPSC-CMs exhibited a significant decrease in viability at 
d25, reaching about only 10% of viable cells at d35 (Fig. 4.5 A), which compromised the 
analysis of cells at this time point. In fact, it has been reported in the literature that increased 
accumulation of fatty acids is associated with cardiac lipotoxicity73. As the increased uptake 
rate outpaces β-oxidation, there is an increased availability of fatty acids for the production of 
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cardiotoxic lipid metabolites that can directly or through activation of downstream pathways 
lead to cellular damage and toxicity73. 
 To evaluate if decreased viability in FAM was a result of lipotoxicity, lipid 
accumulation was quantified through the use of a commercial kit that relies on Nile Red, a 
fluorescent dye specific for lipid droplets74. When compared with cells cultured in other 
media, hiPSC-CMs in FAM had a significant 4-fold increase in lipid droplet content (Fig. 4.5 
B). Furthermore, flux map analysis confirms that most of fatty acid uptake (74%) is diverted 
for accumulation in lipid droplets, instead of b-oxidation (Fig. 4.5 C) even though gene 
expression of enzymes involved in this pathway is up-regulated (Fig. S1).  Moreover central 
carbon metabolism is greatly altered, herein, TCA cycle is mainly fueled by amino acid 
carbon sources, mostly glutamate that replenishes α-ketoglutarate, since most citrate produced 
in TCA is transported to the cytosol. Also, pyruvate acquires an anaplerotic role to sustain 
TCA cycle activity by primarily producing oxaloacetate, as malate is shuttled to the cytosol 
where it is decarboxylated to pyruvate. Additionally, flux values estimated for glycolysis are 
supported by down-regulation of several enzymes involved in this pathway (Fig. S1). Even 
though fatty acids are the main substrate of the adult heart35,52, culture of hiPSC-CMs in FAM 
seems to lead to a metabolic deregulation, which coupled with the lipotoxic effects of fatty 
acid accumulation could justify the decrease in cell viability. 
  Considering that galactose was proved to increase fatty acid oxidation and formation 
of neutral lipids in skeletal muscle cells75, the absence of a marked accumulation of fatty acids 
or low viability in hiPSC-CMs cultured in GFAM suggests that galactose supplementation 
was enough to prevent lipotoxicity by improving oxidative capacity of hiPSC-CMs. Hence, 
improved oxidative capacity decreased fatty acid availability for non-oxidative pathways and 
consequent production of lipotoxic metabolites.  
 In future studies it would be interesting to investigate whether lipotoxicity in FAM 
arises from the medium composition itself or an inadequate adaptation of cells to an oxidative 
metabolism. This hypothesis could be tested by determining if pre-treatment of hiPSC-CMs 
with GFAM during for example 10 days, before switching to FAM, could prevent 
lipotoxicity.  
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Figure 4.5 - Fatty acid rich medium induces lipotoxicity in hiPSC-CMs. (A) Percentage of cell viability in all 
culture conditions tested assessed using the Trypan Blue Exclusion Method. Cell viability is normalized to d15. 
(B) Analysis of lipid droplet content at d30 using a lipid droplet-specific fluorescent dye, Nile Red. Fluorescence 
values were normalized for the values obtained in cells cultivated in GLCM. (C) Metabolic flux map 
highlighting central carbon metabolism of hiPSC-CMs cultivated in FAM at d25. The flux map was determined 
using nonstationary 13C-MFA analysis. Arrow thickness reflects flux values in units of nmol/h/106cell (see Table 
S1 for exact flux values). Up-regulated and down-regulated genes encoding metabolic enzymes are demarked in 
red and green, respectively. Genes were considered enriched based on a fold difference in expression (FC) ≥1.3 
when compared with d15 (see Figure S1 for heatmap of FC from all culture conditions). Data represented as 
mean±SD. *p<0.05; ***p<0.001; ns, not significant. 
 
 
4.4. GFAM improves morphology and structure of hiPSC-CMs 
 Analysis of hiPSC-CMs morphology throughout culture time revealed that in contrast 
with GLCM, cells cultured in the others glucose depleted media exhibit lower surface area 
and circularity, and a higher length-to-width ratio (Fig. 4.6 A-C). Thus hiPSC-CMs cultured 
in these conditions, showed morphological features resembling adult cardiomyocytes, which 
have an elongated rod-like shape with length-to-width ratios in the range of 7-9.542.
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Figure 4.6 – Morphology and structural features of hiPSC-CMs after culture in different media. (A-C) 
Cell structure characterization in terms of cell area (A), circularity index (B) and length-to-width ratio (C). n>70 
cells per condition. Representative images of hPSC-CMs immunostained for cardiac troponin-T (cTnT, red), at 
d35 (D) and d25 (E) of culture in different media. Nuclei (blue) were stained with Hoechst 33342. Scale bars = 
30 μm. Data represented as mean±SD. *p<0.05; **p<0.01; ***p<0.001; ns, not significant. 
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Immunofluorescence microscopy analysis highlights that besides the large area and round 
shape observed, cells in GLCM display disorganized sarcomeres (Fig. 4.6 D-left panel), all of 
which reminiscent of pathogenic hypertrophy44. Therefore, maintenance of hiPSC-CMs in 
glucose rich medium appears to have detrimental effects on maturation not only because cells 
remain highly glycolytic (Fig 4.4 A), resembling human fetal cardiomyocytes32, but also due 
to the development of pathogenic hypertrophy.  
 In contrast, hiPSC-CMs cultured in GFAM and LACM&GFAM exhibited highly 
organized sarcomeres, spanning in parallel across all cell (Fig. 4.6 D-right panels). However, 
in LACM&GFAM the cross-striated pattern of cTnT is less defined. In fact, at d25, cTnT 
staining is very diffuse in LACM&GFAM (Fig. 4.6 E-right panel), contrasting with GFAM 
where a cross-striated pattern of sarcomeres is already evident (Fig. 4.6 E-left panel). This 
data suggests that, culture of hiPSC-CMs in LACM&GFAM until d25 did not suffice to 
induce the same degree of structural maturation as culture in GFAM did. However, at d35 
cells cultured in LACM&GFAM displayed considerable improvements in sarcomere 
organization (Fig. 4.6 D-bottom right panel). Since hiPSC-CMs maintained in the 
LACM&GFAM feeding strategy are cultured in GFAM from d25 to d35, these results 
highlight the importance of GFAM medium composition in hiPSC-CMs structural maturation.  
Therefore, LACM&GFAM could be an appropriate maturation strategy if the purity of the 
initial hiPSC-CM culture is low, as the first 10 days in lactate allow for the metabolic 
selection of hiPSC-CM, as reported previously by others32. Since in this study the starting 
population was highly pure, the rationale of using lactate was to mimic substrate availability 
during heart development35 and ascertain if it would increase maturation. However, this 
strategy proved less efficient than maintaining hiPSC-CMs in GFAM during 20 days. 
 When comparing d35 to d25 in GFAM, hiPSC-CMs features present significant 
improvements in metabolic and structural maturation, raising the question if increased culture 
time in GFAM could bring further improvements in hiPSC-CMs maturation, however this 
notion still requires additional investigation. Nevertheless, culture of hiPSC-CMs in GFAM 
proved to be a time efficient strategy since 20 days of culture were enough to achieve 
substantial improvements in hiPSC-CM structural and metabolic maturation.  
 The work presented in this thesis showed that a simple change in carbon source 
induced a shift to an oxidative metabolism that was accompanied by increased structural 
maturation of hiPSC-CMs, evidencing the link between regulation of metabolism and hiPSC-
CMs maturation in vitro. Furthermore, it is important to mention that in parallel to this work, 
functional analyses of hiPSC-CMs were carried out in collaboration with Dr. Ibrahim 
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Domian, to evaluate calcium, contractility and action potential kinetics and confirm functional 
maturation of hiPSC-CMs. 
 The maturation protocol established in this study holds technical and economic 
advantages over the existing protocols due to its simplicity (a simple medium-exchange 
procedure) and ease of application (does not require specific equipment or addition of 
expensive factors/chemicals). Moreover, it can be easily combined with other approaches, like 
mechanical41 and electrical stimulation42, to further improve hiPSC-CMs maturation in vitro 
by mimicking the wide range of factors that come into play during heart development in vivo. 
Additionally, it is noteworthy that 10 days of culture in GFAM was sufficient to promote 
hiPSC-CM metabolic and structural maturation comparable to what has been described in the 
literature after 80-100 days of culture76. Therefore GFAM treatment constitutes a great 
advance for the maturation of hiPSC-CMs in a time efficient manner. This will strengthen the 
potential of hiPSC-CMs application in cell therapy, drug discovery, toxicity testing and 
cardiac disease modeling. 
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5. Conclusion 
 
 In this study a new approach for hiPSC-CMs maturation was developed by changing 
the carbon source available in cell culture medium. 
 hPSC-CMs remained highly glycolytic regardless of the evident development in 
metabolic machinery during differentiation. However, upon culture in distinct glucose 
depleted media, hiPSC-CMs exhibited remarkable metabolic plasticity switching to an 
oxidative metabolism. Therefore, these results suggest that when the main substrate available 
in the media is glucose, the preferred consumption of this substrate restricts hiPSC-CMs 
metabolism to a glycolytic profile. 
 From the distinct selection of media tested, culture in GFAM was the most efficient 
strategy in improving hiPSC-CMs maturation in vitro, with cells displaying a more 
energetically efficient oxidative metabolism, elongated morphologies and organized 
sarcomeric structures. Moreover, supplementation of fatty acid medium with galactose 
increased hiPSC-CMs oxidative capacity, improving fatty acid oxidation and preventing 
lipotoxic effects of excessive fatty acid accumulation. In the standard glucose supplemented 
medium, hiPSC-CMs maintained a fetal-like metabolic profile and showed features that 
resemble pathogenic hypertrophy. These results highlight the regulatory role of metabolism in 
a wide range of vital cellular functions. 
 To date, no other study has established a quantitative metabolic network model, using 
nonstationary 13C-MFA, of hiPSC-CMs cultured in distinct carbon sources, nor the extent to 
which this change modulates metabolic and structural maturation of hiPSC-CMs, as assessed 
herein. Furthermore, 10 days of culture in GFAM was sufficient to promote hiPSC-CM 
metabolic and structural maturation comparable to what has been described in the literature 
after long term culture. Thus, the protocol developed herein represents a relevant step forward 
in time efficient maturation of hiPSC-CMs, bridging closer the gap between hiPSC-CMs and 
cell therapy or pre-clinical applications. 
 Future investigations relying on the combination of this maturation strategy with a 3D 
cell culture approach using environmentally controlled bioreactors will be pursued as a 
promising strategy towards the scalable production of more mature hiPSC-CMs in vitro. 
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7. Annexes 
 
Table S1 - Metabolic network reactions and simulated fluxes determined by nonstationary 13C-
MFA. Flux values are shown in units of nmol/h/106cell. Negative flux values indicate that net 
direction is reverse to the direction indicated. 
 
Reactions 
Flux values 
GLCM d35 GFAM d35 FAM d35 
v1 G6P <-> F6P 220.45 9.01 0.00 
v2 F6P -> FBP 242.93 22.68 0.00 
v3 FBP <-> DHAP + GAP 242.93 22.68 0.00 
v4 DHAP <-> GAP 242.93 22.68 0.00 
v5 GAP <-> 3PG 497.10 52.20 0.00 
v6 3PG <-> PEP 496.94 52.20 0.00 
v7 PEP -> Pyr.c 496.94 52.20 0.00 
v8 Pyr.c <-> Pyr.m 5.59 67.33 102.50 
v9 G6P -> P5P + CO2 33.72 20.50 0.00 
v10 P5P + P5P <-> GAP + S7P 11.24 6.83 0.00 
v11 S7P + GAP <-> E4P + F6P 11.24 6.83 0.00 
v12 E4P + P5P <-> GAP + F6P 11.24 6.83 0.00 
v13 Pyr.c <-> Lac 491.38 0.00 0.00 
v14 Pyr.c <-> Ala -0.03 -11.02 0.00 
v15 Pyr.m -> AcCoA.m + CO2 5.59 67.15 30.01 
v16 OAA.m + AcCoA.m -> Cit.m 14.14 87.87 55.04 
v17 Cit.m <-> AKG + CO2 14.09 87.44 21.93 
v18 AKG -> SucCoA + CO2 14.70 87.03 42.92 
v19 SucCoA <-> Suc 14.70 87.03 42.92 
v20 Suc <-> Fum.m 14.70 87.27 45.30 
v21 Fum.m <-> Mal.m 14.70 87.69 51.66 
v22 Mal.m <-> OAA.m 14.14 87.69 -17.45 
v23 Mal.c -> Pyr.c + CO2 0.00 0.43 102.22 
v24 Pyr.m + CO2 -> OAA.m 0.00 0.18 72.49 
v25 Gln <-> Glu 0.99 2.47 3.83 
v26 AKG <-> Glu -0.61 0.41 -20.99 
v27 Asn <-> Asp 0.00 0.00 0.00 
v28 3PG -> Ser 0.16 0.00 0.00 
v29 Ser -> Pyr.c 0.00 3.68 0.28 
v30 Ser <-> Gly + C1 -1.78 -1.02 -2.39 
v31 Glu <-> Pro 0.00 0.98 -10.49 
v32 Val + CO2 -> Suc + CO2 + CO2 0.00 0.13 0.00 
v33 
Ile + CO2 -> Suc + AcCoA.m + 
CO2 
0.00 0.00 0.00 
v34 
Leu + CO2 -> AcCoA.m + 
AcCoA.m + AcCoA.m + CO2 
2.25 1.54 0.00 
v35 Thr -> AcCoA.m + Gly 0.00 0.34 3.93 
v36 Phe -> Tyr 0.00 0.06 0.00 
35 
 
v37 
Tyr -> Fum.m + AcCoA.m + 
AcCoA.m + CO2 
0.00 0.42 6.36 
v38 
Met + Ser + CO2 -> Suc + Cys.snk + 
CO2 + C1 
0.00 0.12 2.39 
v39 
Lys -> CO2 + CO2 + AcCoA.m + 
AcCoA.m 
0.90 2.36 0.00 
v40 His -> Glu + C1 1.78 0.90 0.00 
v41 Arg -> Glu + Urea.snk 59.81 58.67 0.00 
v42 Glu + CO2 -> Arg 63.96 61.80 0.00 
v43 Glc.ext -> G6P 254.17 0.00 0.00 
v44 Lac.ext <-> Lac -491.38 0.00 0.00 
v45 Ala.ext <-> Ala 0.03 11.02 0.00 
v46 Gln.ext -> Gln 0.99 2.47 3.83 
v47 Glu.ext <-> Glu 1.99 0.33 6.68 
v48 Ser.ext <-> Ser -1.93 2.78 0.28 
v49 Gly.ext <-> Gly 1.78 0.67 -1.55 
v50 Pro.ext <-> Pro 0.00 -0.98 10.49 
v51 Val.ext -> Val 0.00 0.13 0.00 
v52 Ile.ext -> Ile 0.00 0.00 0.00 
v53 Leu.ext -> Leu 2.25 1.54 0.00 
v54 Thr.ext -> Thr 0.00 0.34 3.93 
v55 Phe.ext -> Phe 0.00 0.06 0.00 
v56 Tyr.ext -> Tyr 0.00 0.35 6.36 
v57 Met.ext -> Met 0.00 0.12 2.39 
v58 Lys.ext -> Lys 0.90 2.36 0.00 
v59 His.ext -> His 1.78 0.90 0.00 
v60 Arg.ext <-> Arg -4.15 -3.13 0.00 
v61 Asp <-> OAA.c -0.61 0.00 0.00 
v62 Cit.c -> OAA.c + AcCoA.c 0.05 0.43 33.11 
v63 CO2.ext <-> CO2 -5.94 -50.84 -130.96 
v64 AcCoA.c -> FA.ext 0.05 0.43 33.11 
v65 PA.ext -> PA.c 0.00 5.21 16.74 
v66 
PA.m -> AcCoA.m + AcCoA.m + 
AcCoA.m + AcCoA.m + AcCoA.m 
+ AcCoA.m + AcCoA.m + 
AcCoA.m  
0.00 4.92 5.18 
v67 OA.ext -> OA.c 0.00 5.51 15.60 
v68 
OA.m -> AcCoA.m + AcCoA.m + 
AcCoA.m + AcCoA.m + AcCoA.m 
+ AcCoA.m + AcCoA.m + 
AcCoA.m + AcCoA.m  
0.00 5.29 3.20 
v69 Gal.ext -> G6P 0.00 29.51 0.00 
v70 Cit.c -> Cit.snk 0.00 0.00 0.00 
v71 Mal.m <-> Mal.c 0.56 0.00 69.11 
v72 0*Mal.c -> Mal.s 3.93 0.00 0.00 
v73 0*Mal.m -> Mal.s 96.07 100.00 100.00 
v74 Mal.s -> Sink 100.00 100.00 100.00 
v75 0*Fum.c -> Fum.s 14.02 30.52 0.00 
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Abbreviations: c. cytosolic; m. mitochondrial; s. sink. 
Fumarate and succinate were considered as symmetric molecules during flux estimation.  
Compartmentalization of Pyr, Fum, Mal, Cit, AcCoA, OAA, AO and AP pools were taken into 
account in the model. Sink pools were considered for metabolites that could not be balanced. 
Balanced metabolite pools: G6P, F6P, FBP, DHAP, GAP, 3PG, PEP, Pyr.c, Pyr.m, P5P, CO2, S7P, 
E4P, Lac, Ala, AO.c, AO.m, AP.c, AP.m, AcCoA.c, AcCoA.m, OAA.c,OAA.m, Pyr.c, Pyr.m, Cit.c, 
Cit.m, AKG, SucCoA, Suc, Fum.c, Fum.m, Mal.c,Mal.m, Gln, Glu, Asn, Asp, Ser, Gly, C1, Pro, Val, 
Ile, Leu, Thr, Phe, Tyr, Met, Lys, His, Arg.  
Unbalanced metabolite pools: AO.ext, AP.ext, Ao.snk, Ap.snk, Cit.snk, FA.ext, CO2.ext, Glc.ext, 
Gal.ext Lac.ext, Ala.ext, Gln.ext, Glu.ext, Asp.ext, Asn.ext, Ser.ext, Gly.ext, Pro.ext, Val.ext, Ile.ext, 
Leu.ext, Thr. ext, Phe.ext, Tyr.ext, Met.ext, Lys.ext, His.ext, Arg.ext, Cys.snk, Urea.snk. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
v76 0*Fum.m -> Fum.s 85.98 69.48 100.00 
v77 Fum.s -> Sink 100.00 100 100.00 
v78 Mal.c <-> Fum.c 0.00 0.00 0.00 
v79 OAA.c <-> Mal.c -0.56 0.43 33.11 
v80 Asp.ext <-> Asp -0.61 0.00 0.00 
v81 0*Cit.c -> Cit.s 0.00 96.40 0.00 
v82 0*Cit.m -> Cit.s 100.00 3.60 100.00 
v83 Cit.s -> Sink 100.00 100.00 100.00 
v84 Cit.c <-> Cit.m -0.05 -0.43 -33.11 
v85 PA.c -> PA.m 0.00 0.62 0.65 
v86 PA.c -> PA.snk 0.00 0.59 0.36 
v87 OA.c -> OA.m 0.00 0.04 1.45 
v88 OA.c -> OA.snk 0.00 0.02 1.38 
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Figure S1 - Effect of culture media composition on metabolic gene expression. Heat map of differentially 
expressed genes associated with metabolic pathways. Heatmap shows averaged values from n=2. In all analyses, 
genes were considered enriched based on a fold difference in expression (FC) ≥1.3 when compared with d15. 
Green and red represent down- and up-regulation, respectively. 
 
